XOMA Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XOMA stock.
View analyst ratings for XOMA or view top-rated stocks.

Wall Street analysts have given XOMA a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but XOMA wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

XOMA is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for XOMA.

XOMA Co. (NASDAQ:XOMA) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.04. The biotechnology company earned $0.90 million during the quarter, compared to analysts' expectations of $2.09 million. XOMA had a trailing twelve-month return on equity of 5.88% and a net margin of 16.11%.
View XOMA's earnings history.

XOMA's stock was trading at $19.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have increased by 18.7% and is now trading at $23.15.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued twelve-month target prices for XOMA's stock. Their forecasts range from $22.00 to $56.00. On average, they expect XOMA's share price to reach $44.67 in the next twelve months. This suggests a possible upside of 92.9% from the stock's current price.
View analysts' price targets for XOMA or view top-rated stocks among Wall Street analysts.

11 employees have rated XOMA CEO John Varian on Glassdoor.com. John Varian has an approval rating of 73% among XOMA's employees.

Some companies that are related to XOMA include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of XOMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), TransEnterix (TRXC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

XOMA's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (6.45%), BlackRock Inc. (4.04%), Vanguard Group Inc. (3.46%), Opaleye Management Inc. (3.04%), Geode Capital Management LLC (1.24%) and State Street Corp (1.06%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Matthew D Perry, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends for XOMA.

XOMA stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., BlackRock Inc., JPMorgan Chase & Co., Bank of America Corp DE, Price T Rowe Associates Inc. MD, California State Teachers Retirement System, and Deutsche Bank AG. Company insiders that have sold XOMA company stock in the last year include Bvf Partners L P/Il, James R Neal, and Thomas M Burns.
View insider buying and selling activity for XOMA or view top insider-selling stocks.

XOMA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Nuveen Asset Management LLC, Vanguard Group Inc., Morgan Stanley, and Morgan Stanley. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, Matthew D Perry, and Value Fund L P Biotechnology.
View insider buying and selling activity for XOMA or or view top insider-buying stocks.

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XOMA stock can currently be purchased for approximately $23.15.

XOMA has a market capitalization of $261.85 million and generates $29.39 million in revenue each year. The biotechnology company earns $13.30 million in net income (profit) each year or $0.78 on an earnings per share basis.

XOMA employs 10 workers across the globe.

XOMA was founded in 1981.

The official website for XOMA is www.xoma.com.

XOMA is headquartered at 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608.

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 204-7200 or via email at [email protected].